ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...

Results showed treatment with insulin efsitora was noninferior to insulin degludac based on reduction in HbA1c at 52 weeks. Once-weekly insulin efsitora was found to be as effective as daily basal ...

Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. We conducted a ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky for those with type 1 diabetes, the phase III QWINT-2 and -5 trials showed.

The list price is $137.35 per vial. This story is from Kaiser Health News When Erin Gilmer filled her insulin prescription at a Denver-area Walgreens in January, she paid $8.50. U.S. taxpayers paid ...

Prices for insulin, the essential drug for treating diabetes, have plummetted to their lowest levels in a decade following a rise in generic options. Insulin prices averaged 19 cents per unit as of ...

Dr Anne Peters of the Keck School of Medicine of the University of Southern California reports on the latest research on insulin therapy in adults with type 2 diabetes (T2D), presented at the 2023 ...

July 13 (Reuters) - Americans without health insurance pay an average of $98 for Eli Lilly’s generic insulin despite the company’s May 1 pledge to cut its list price to $25 per vial, according to a ...

Over the course of 52 weeks, people with type 2 diabetes saw a greater average reduction in HbA1c with icodec compared with glargine U100 (estimated between-group difference -0.19%, 95% CI -0.36% to ...

Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to sell state-branded ...